Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.
 

Baras B, Benoit MA, Dupre L, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G
 

Laboratoire de Pharmacie Galenique, Industrielle et Officinale, Ecole de Pharmacie, Universite Catholique de Louvain, B-1200 Brussels, Belgium.
 

The purpose of this work was to assess the immunogenicity of a single nasal or oral administration of recombinant 28-kDa glutathione S-transferase of Schistosoma mansoni (rSm28GST) entrapped by poly(lactide-co-glycolide) (PLG)- or polycaprolactone (PCL)-biodegradable microparticles. Whatever the polymer and the route of administration used, the equivalent of 100 &mgr;g of entrapped rSm28GST induced a long-lasting and stable antigen-specific serum antibody response, with a peak at 9 to 10 weeks following immunization. Isotype profiles were comparable, with immunoglobulin G1 being the predominant isotype produced. The abilities of specific antisera to neutralize the rSm28GST enzymatic activity have been used as criteria of immune response quality. Pooled 10-week sera from mice receiving PLG microparticles by the nasal or oral route neutralized the rSm28GST enzymatic activity, whereas sera of mice receiving either PCL microparticles, free rSm28GST, or empty microparticles inefficiently neutralized this enzymatic activity. Finally, this study shows that a single administration of these microparticles could provide distinct and timely release pulses of microencapsulated antigen, which might greatly facilitate future vaccine development.
 

PMID: 10225935, UI: 99242860